• 1.重慶醫(yī)科大學附屬第一醫(yī)院普外科 (重慶400016);;
  • 2.重慶醫(yī)科大學基礎醫(yī)學院病理學教研室;

【摘要】目的 研究乳腺癌組織中P-gp、nm23和p53的變化規(guī)律及與乳腺癌復發(fā)的關(guān)系。
方法應用免疫組化方法檢測10例乳腺纖維腺瘤(纖維腺瘤組)和47例乳腺癌病變組織中P-gp、nm23和p53 的表達,47例乳腺癌中18例隨訪3~5年無復發(fā)(無復發(fā)組),29例3年內(nèi)復發(fā)(復發(fā)組),并比較其表達陽性率和表達強度的差異。
結(jié)果乳腺癌復發(fā)組nm23表達陽性率較纖維腺瘤組低(P<0.05),其陽性表達強度較無復發(fā)組低。復發(fā)組和無復發(fā)組p53表達陽性率均較纖維腺瘤組高(P<0.05),復發(fā)組p53陽性表達強度高于無復發(fā)組(P<0.05)。復發(fā)組和無復發(fā)組Pgp表達陽性率與纖維腺瘤組比較差異無顯著性意義,但其陽性表達強度較纖維腺瘤組低(P<0.01,P<0.025)。
結(jié)論p53過表達和nm23低表達對預測乳腺癌復發(fā)具有一定價值。

引用本文: 孫治君,周鑫,姚榛祥,管小琴,李圓圓. P-gp、nm23和p53聯(lián)合檢測判斷乳腺癌預后的價值. 中國普外基礎與臨床雜志, 2005, 12(3): 244-248. doi: 復制

版權(quán)信息: ?四川大學華西醫(yī)院華西期刊社《中國普外基礎與臨床雜志》版權(quán)所有,未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Arceci RJ, Stieglitz K, Bras J, et al. Monoclonal antibody to an external epitope of the human mdr1 Pglycoprotein [J]. Cancer Res, 1993; 53(2)∶310.
2. Ling V. Pglycoprotein and resistance to anticancer drugs [J]. Cancer, 1992; 69(10)∶2603.
3. Royds JA, Cross SS, Silcodks PB, et al. nm23 ‘a(chǎn)ntimetastatic’ gene product expression in breast carcinoma [J]. J Pathol, 1994; 172(3)∶261.
4. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognostic in breast cancer [J]. J Natl Cancer Inst, 1992; 84(11)∶845.
  1. 1. Arceci RJ, Stieglitz K, Bras J, et al. Monoclonal antibody to an external epitope of the human mdr1 Pglycoprotein [J]. Cancer Res, 1993; 53(2)∶310.
  2. 2. Ling V. Pglycoprotein and resistance to anticancer drugs [J]. Cancer, 1992; 69(10)∶2603.
  3. 3. Royds JA, Cross SS, Silcodks PB, et al. nm23 ‘a(chǎn)ntimetastatic’ gene product expression in breast carcinoma [J]. J Pathol, 1994; 172(3)∶261.
  4. 4. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognostic in breast cancer [J]. J Natl Cancer Inst, 1992; 84(11)∶845.